The DOI matches its Crossref record; 34 of the 36 references it cites were found in a registry or an index.
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Open accessAbstract
BACKGROUND: Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell carcinoma who had received previous treatment. METHODS: A total of 821 patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy were randomly assigned (in a 1:1 ratio) to receive 3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks or a 10-mg everolimus tablet orally once daily. The primary end point was overall survival. The secondary end points included the objective response rate and safety. RESULTS: The median overall survival was 25.0 months (95% confidence interval [CI], 21.8 to not estimable) with nivolumab and 19.6 months (95% CI, 17.6 to 23.1) with everolimus. The hazard ratio for death with nivolumab versus everolimus was 0.73 (98.5% CI, 0.57 to 0.93; P=0.002), which met the prespecified criterion for superiority (P≤0.0148). The objective response rate was greater with nivolumab than with everolimus (25% vs. 5%; odds ratio, 5.98 [95% CI, 3.68 to 9.72]; P<0.001). The median progression-free survival was 4.6 months (95% CI, 3.7 to 5.4) with nivolumab and 4.4 months (95% CI, 3.7 to 5.5) with everolimus (hazard ratio, 0.88; 95% CI, 0.75 to 1.03; P=0.11). Grade 3 or 4 treatment-related adverse events occurred in 19% of the patients receiving nivolumab and in 37% of the patients receiving everolimus; the most common event with nivolumab was fatigue (in 2% of the patients), and the most common event with everolimus was anemia (in 8%). CONCLUSIONS: Among patients with previously treated advanced renal-cell carcinoma, overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus. (Funded by Bristol-Myers Squibb; CheckMate 025 ClinicalTrials.gov number, NCT01668784.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immune checkpoint blockade (ICB), especially targeting the inhibitory receptor programmed cell death 1 (PD-1) expressed on CD8+ T cells, is a highly effective immunotherapy for various cancers.”
From Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“Primary resistance to ICI is common in patients with both RCC and NSCLC, ranging from 35% to 44% and remains unpredictable [1,3].”
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [3]
In the citing paper
“At present, antibodies blocking PD-1 or its ligand PD-L1 have been approved to treat various solid and hematologic malignancies (Table 1) [7–12].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationHapeman, D. E., & Agresti, A. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,407
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645
Self-citation
Cited by
Sorted by citations
Items 601–700 of 1,022
Tay, R. Y., Blackley, E., McLean, C., Moore, M., Bergin, P., Gill, S., & Haydon, A. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.253 · Cited by 119
Dietary Protein Restriction Reprograms Tumor-Associated Macrophages and Enhances Immunotherapy
Orillion, A. R., Damayanti, N. P., Shen, L., Adelaiye-Ogala, R. M., Affronti, H. C., Elbanna, M., Chintala, S., Ciesielski, M. J., Fontana, L., Kao, C. H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0980 · Cited by 121
Recent advances in the clinical development of immune checkpoint blockade therapy
Ghahremanloo, A., Soltani, A., Modaresi, S. M. S., & Hashemy, S. I. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00456-w · Cited by 119
Tumor Vasculatures: A New Target for Cancer Immunotherapy
Liu, Z., Wang, Y., Huang, Y., Kim, B. Y. S., Shan, H., Wu, D., & Jiang, W. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.07.001 · Cited by 122
Wang, Y., Zhong, X., He, X., Hu, Z., Huang, H., Chen, J., Chen, K., Zhao, S., Wei, P., & Li, D. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02729-7 · Cited by 131
Griguolo, G., Pascual, T., Dieci, M. V., Guarneri, V., & Prat, A. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0548-6 · Cited by 119
George, J., Bajaj, D., Sankaramangalam, K. P., Yoo, J. W., Joshi, N. S., Gettinger, S. N., Price, C. C., & Farrell, J. J. (2019) · Pancreatology · doi:10.1016/j.pan.2019.04.015 · Cited by 118
Shah, N. J., Al‐Shbool, G., Blackburn, M. J., Cook, M. R., Belouali, A., Liu, S. V., Madhavan, S., He, A. R., Atkins, M. B., Gibney, G. T., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0771-1 · Cited by 119
Immune-Related Adverse Effects of Cancer Immunotherapy— Implications for Rheumatology
Cappelli, L. C., Shah, A. A., & Bingham, C. O. (2016) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2016.09.007 · Cited by 118
The Future of Immune Checkpoint Cancer Therapy After PD-1 and CTLA-4
Hahn, A. W., Gill, D. M., Pal, S. K., & Agarwal, N. (2017) · Immunotherapy · doi:10.2217/imt-2017-0024 · Cited by 119
Merkel cell carcinoma: An update and review
Tello, T. L., Coggshall, K., Yom, S. S., & Yu, S. S. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.12.004 · Cited by 117
Gatalica, Z., Xiu, J., Swensen, J. J., & Vranić, S. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.02.021 · Cited by 118
Correlation between sex and efficacy of immune checkpoint inhibitors ( PD ‐1 and CTLA ‐4 inhibitors)
Wu, Y. C., Ju, Q., Jia, K., Yu, J., Shi, H. M., Wu, H., & Jiang, M. (2018) · International Journal of Cancer · doi:10.1002/ijc.31301 · Cited by 118
Predictors of Immunotherapy-Induced Immune-Related Adverse Events
Kartolo, A., Sattar, J., Sahai, V., Baetz, T. D., & Lakoff, J. M. (2018) · Current Oncology · doi:10.3747/co.25.4047 · Cited by 119
Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors
Kennedy, L. C., Bhatia, S., Thompson, J. A., & Grivas, P. D. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.7310 · Cited by 117
Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?
Rosenblatt, J. M., & Avigan, D. (2016) · Blood · doi:10.1182/blood-2016-08-731885 · Cited by 117
HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study
Naranbhai, V., Viard, M., Dean, M. C., Groha, S., Braun, D. A., Labaki, C., Shukla, S. A., Yuki, Y., Shah, P. K., Chin, K. M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00582-9 · Cited by 119
Self-citationImmune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Day, D., & Hansen, A. R. (2016) · BioDrugs · doi:10.1007/s40259-016-0204-3 · Cited by 117
Nishino, M., Ramaiya, N. H., Chambers, E. S., Adeni, A. E., Hatabu, H., Janne, P. A., Hodi, F. S., & Awad, M. M. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0193-2 · Cited by 117
The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma
DiDomenico, J. D., Lamano, J. B., Oyon, D. E., Li, Y., Veliceasa, D., Kaur, G., Ampie, L., Choy, W., Lamano, J. B., & Bloch, O. G. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1448329 · Cited by 118
Multiple sclerosis outcomes after cancer immunotherapy
García, C. R., Jayswal, R. D., Adams, V. R., Anthony, L. B., & Villano, J. L. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02060-8 · Cited by 117
Motzer, R. J., Choueiri, T. K., McDermott, D. F., Powles, T. B., Vano, Y. A., Gupta, S. K., Yao, J., Han, G. C., Ammar, R., Papillon‐Cavanagh, S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004316 · Cited by 117
Self-citationMedical treatment of renal cancer: new horizons
Greef, B., & Eisen, T. G. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.230 · Cited by 114
Long, J., Lin, J., Wang, A., Wu, L., Zheng, Y., Yang, X., Wan, X., Xu, H., Chen, S., & Zhao, H. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0511-2 · Cited by 115
Masini, C., Iotti, C., Giorgi, U. D., Bellia, S. R., Buti, S., Salaroli, F., Zampiva, I., Mazzarotto, R., Mucciarini, C., Vitale, M. G., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.09.016 · Cited by 119
Self-citationTowards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics
Collins, D. C., Sundar, R., Lim, J. S. J., & Yap, T. A. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.012 · Cited by 116
O’Connor, J. M., Fessele, K. L., Steiner, J., Seidl-Rathkopf, K., Carson, K. R., Nussbaum, N. C., Yin, E. S., Adelson, K. B., Presley, C. J., Chiang, A. C., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0798 · Cited by 114
Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma
McKay, R. R., Bossé, D., & Choueiri, T. K. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.0253 · Cited by 115
Self-citationUpdated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy
Powles, T. B., Staehler, M. D., Ljungberg, B., Bensalah, K., Canfield, S. E., Dabestani, S., Giles, R. H., Hofmann, F., Hora, M., Kuczyk, M. A., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.10.017 · Cited by 113
Murakami, N., Borges, T. J., Yamashita, M., & Riella, L. V. (2016) · Clinical Kidney Journal · doi:10.1093/ckj/sfw024 · Cited by 113
PD-1/PD-L1 pathway inhibitors in advanced prostate cancer
Velho, P. I., & Antonarakis, E. S. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1464388 · Cited by 114
Myositis as an adverse event of immune checkpoint blockade for cancer therapy
Shah, M., Tayar, J. H., Abdel‐Wahab, N., & Suarez-Almazor, M. E. (2018) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2018.05.006 · Cited by 112
Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
Jelı́nek, T., Paiva, B., & Hájek, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02431 · Cited by 115
Pignon, J., Jegede, O. A., Shukla, S. A., Braun, D. A., Horak, C. E., Wind‐Rotolo, M., Ishii, Y., Catalano, P. J., Grosha, J., Flaifel, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3206 · Cited by 117
Self-citationZafar, S., Hafeez, A., Shah, H., Mutiullah, I., Ali, A., Khan, K., Figueroa‐González, G., Reyes‐Hernández, O. D., Granados, L. I. Q., Peña‐Corona, S. I., et al. (2025) · European journal of medical research · doi:10.1186/s40001-025-03003-6 · Cited by 123
IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy
Johnson, D., Patel, A. B., Uemura, M. I., Trinh, V. A., Jackson, N., Zobniw, C. M., Tetzlaff, M. T., Hwu, P., Curry, J. L., & Diab, A. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0682 · Cited by 111
The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
Botticelli, A., Onesti, C. E., Zizzari, I. G., Cerbelli, B., Sciattella, P., Occhipinti, M. A., Roberto, M., Pietro, F. R. D., Bonifacino, A., Ghidini, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22242 · Cited by 113
Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade
Reynolds, K. L., Thomas, M. F., & Dougan, M. L. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0174 · Cited by 112
Grassadonia, A., Sperduti, I., Vici, P., Iezzi, L., Brocco, D., Gamucci, T., Pizzuti, L., Maugeri‐Saccà, M., Marchetti, P., Cognetti, G., et al. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7120542 · Cited by 112
Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
Cadranel, J. L., Canellas, A., Matton, L., Darrason, M., Parrot, A., Naccache, J., Lavolé, A., Ruppert, A.-M., & Fallet, V. (2019) · European Respiratory Review · doi:10.1183/16000617.0058-2019 · Cited by 113
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
Ciciola, P., Cascetta, P., Bianco, C., Formisano, L., & Bianco, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030675 · Cited by 113
Under-reporting of harm in clinical trials
Šeruga, B., Templeton, A. J., Badillo, F. E. V., Ocaña, A., Amir, E., & Tannock, I. F. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00152-2 · Cited by 110
Choi, Y., Kim, J. W., Nam, K. H., Han, S.-H., Kim, J., Ahn, S.-H., Park, D. J., Lee, K., Lee, H. S., & Kim, H. (2016) · Gastric Cancer · doi:10.1007/s10120-016-0642-0 · Cited by 110
Ladomersky, E., Zhai, L., Lauing, K. L., Bell, A., Xu, J., Kocherginsky, M., Zhang, B., Wu, J. D., Podojil, J. R., Platanias, L. C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3874 · Cited by 110
Karachi, A., Yang, C., Dastmalchi, F., Sayour, E. J., Huang, J., Azari, H., Long, Y., Flores, C., Mitchell, D. A., & Rahman, M. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz015 · Cited by 113
Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma
Carril-Ajuria, L., Santos, M., Roldán‐Romero, J. M., Rodríguez‐Antona, C., & de Velasco, G. (2019) · Cancers · doi:10.3390/cancers12010016 · Cited by 109
Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review
Onoyama, T., Takeda, Y., Yamashita, T., Hamamoto, W., Sakamoto, Y., Koda, H., Kawata, S., Matsumoto, K., & Isomoto, H. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i3.353 · Cited by 110
Systematic Review of Immune Checkpoint Inhibition in Urological Cancers
Rijnders, M., de Wit, R., Boormans, J. L., Lolkema, M. P., & van der Veldt, A. A. M. (2017) · European Urology · doi:10.1016/j.eururo.2017.06.012 · Cited by 109
Feng, Y., Wang, X., Bajaj, G., Agrawal, S., Bello, A., Lestini, B. J., Finckenstein, F. G., Park, J.-S., & Roy, A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2842 · Cited by 109
Global mapping of cancers: The Cancer Genome Atlas and beyond
Ganini, C., Amelio, I., Bertolo, R. G., Bove, P., Buonomo, O. C., Candi, E., Cipriani, C., Daniele, N. D., Juhl, H. H., Mauriello, A., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13056 · Cited by 110
Targeting senescence as an anticancer therapy
Bousset, L., & Gil, J. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13312 · Cited by 113
Cancer cell-intrinsic mechanisms driving acquired immune tolerance
Ghorani, E., Swanton, C., & Quezada, S. A. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.004 · Cited by 116
Ligero, M., Garcia-Ruiz, A., Viaplana, C., Villacampa, G., Raciti, M. V., Landa, J., Matos, I., Martin-Liberal, J., Ochoa-de-Olza, M., Hierro, C., et al. (2021) · Radiology · doi:10.1148/radiol.2021200928 · Cited by 107
Feldmeyer, L., Hudgens, C. W., Ray-Lyons, G., Nagarajan, P., Aung, P. P., Curry, J. L., Torres-Cabala, C. A., Mino, B., Rodriguez‐Canales, J., Reuben, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0392 · Cited by 107
Knox, J. J., Barrios, C. H., Kim, T. M., Cosgriff, T. M., Srimuninnimit, V., Pittman, K. B., Sabbatini, R., Rha, S. Y., Flaig, T. W., Page, R. D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx075 · Cited by 107
Self-citationMechanisms of Tumor Cell–Intrinsic Immune Evasion
Spranger, S., & Gajewski, T. F. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050606 · Cited by 113
Tumor location impacts immune response in mouse models of colon cancer
Zhao, X., Li, L., Starr, T. K., & Subramanian, S. (2017) · Oncotarget · doi:10.18632/oncotarget.18423 · Cited by 111
Efron, P. A., Mohr, A. M., Bihorac, A., Horiguchi, H., Hollen, M. K., Segal, M. S., Baker, H. V., Leeuwenburgh, C., Moldawer, L. L., Moore, F. A., et al. (2018) · Surgery · doi:10.1016/j.surg.2018.04.011 · Cited by 107
Tostivint, E. P., Latouche, A., Vaflard, P., Ricci, F., Loirat, D., Hescot, S., Sablin, M., Rouzier, R., Kamal, M. T., Morel, C., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00114 · Cited by 112
Hou, Y., Chao, Y., Hsieh, M.-H., Tung, H., Wang, H., & Shan, Y. (2019) · Cancers · doi:10.3390/cancers11040541 · Cited by 109
Vogelzang, N. J., Olsen, M. R., McFarlane, J. J., Arrowsmith, E. R., Bauer, T. M., Jain, R., Somer, B. G., Lam, E. T., Kochenderfer, M. D., Molina, A. M., et al. (2020) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2020.05.006 · Cited by 107
Self-citationCombinatorial approach to cancer immunotherapy: strength in numbers
Vilgelm, A. E., Johnson, D. B., & Richmond, A. J. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.5ri0116-013rr · Cited by 109
Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review
Jhaveri, K. D., Wanchoo, R., Sakhiya, V., Ross, D. W., & Fishbane, S. N. (2016) · Kidney International Reports · doi:10.1016/j.ekir.2016.09.055 · Cited by 106
Feng, S., Coward, J. I. G., McCaffrey, E., Coucher, J., Kalokerinos, P. N., & O'Byrne, K. J. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.08.007 · Cited by 107
Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings
Wang, G. X., Kurra, V., Gainor, J. F., Sullivan, R. J., Flaherty, K. T., Lee, S. I., & Fintelmann, F. J. (2017) · Radiographics · doi:10.1148/rg.2017170085 · Cited by 107
Lucas, J., Hsieh, T., Halicka, H. D., Darżynkiewicz, Z., & WU, J. M. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4512 · Cited by 106
Petrelli, F., Ardito, R., Borgonovo, K., Lonati, V., Cabiddu, M., Ghilardi, M., & Barni, S. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.07.129 · Cited by 107
Endris, V., Buchhalter, I., Allgäuer, M., Rempel, E., Lier, A., Volckmar, A., Kirchner, M., von Winterfeld, M., Leichsenring, J., Neumann, O., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.32002 · Cited by 107
Liu, X., Li, M., Wang, X., Dang, Z., Jiang, Y., Wang, X., Kong, Y., & Yang, Z. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02426-5 · Cited by 106
Molecular imaging biomarkers for immune checkpoint inhibitor therapy
van de Donk, P. P., de Ruijter, L. K., Hooge, M. N. L., Brouwers, A. H., van der Wekken, A. J., Oosting, S. F., Fehrmann, R. S. N., de Groot, D. J. A., & de Vries, E. G. E. (2020) · Theranostics · doi:10.7150/thno.38339 · Cited by 109
The Tumor Immune Microenvironment in Clear Cell Renal Cell Carcinoma
Monjarás-Ávila, C. U., Lorenzo‐Leal, A. C., Luque-Badillo, A. C., D’Costa, N. M., Chavez-Munoz, C. I., & Bach, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097946 · Cited by 110
Immune‐Related Adverse Events From Immune Checkpoint Inhibitors
Marrone, K. A., Ying, W., & Naidoo, J. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.394 · Cited by 106
Renal cell carcinoma for the nephrologist
Perazella, M. A., Dreicer, R., & Rosner, M. H. (2018) · Kidney International · doi:10.1016/j.kint.2018.01.023 · Cited by 106
Immune checkpoint inhibitors for urothelial carcinoma
Kim, H. S., & Seo, H. K. (2018) · Korean journal of urology · doi:10.4111/icu.2018.59.5.285 · Cited by 106
PD-1 and LAG-3 Dominate Checkpoint Receptor–Mediated T-cell Inhibition in Renal Cell Carcinoma
Zelba, H., Bedke, J., Hennenlotter, J., Mostböck, S., Zettl, M., Zichner, T., Chandran, A., Stenzl, A., Rammensee, H., & Gouttefangeas, C. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0146 · Cited by 105
Eng, L., Sutradhar, R., Niu, Y., Liu, N., Liu, Y., Kaliwal, Y., Powis, M., Liu, G., Peppercorn, J. M., Bedard, P. L., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00074 · Cited by 106
Anantharaman, A., Friedlander, T. W., Lu, D. M., Krupa, R., Premasekharan, G., Hough, J., Edwards, M., Paz, R., Lindquist, K. J., Graf, R. P., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2758-3 · Cited by 105
Combining radiotherapy with immunotherapy: the past, the present and the future
Limbergen, E. J. V., Ruysscher, D. D., Pimentel, V. O., Marcus, D., Berbée, M., Hoeben, A., Rekers, N. H., Theys, J., Yaromina, A., Dubois, L. J., et al. (2017) · British Journal of Radiology · doi:10.1259/bjr.20170157 · Cited by 105
Tamura, K., Hasegawa, K., Katsumata, N., Matsumoto, K., Mukai, H., Takahashi, S., Nomura, H., & Minami, H. (2019) · Cancer Science · doi:10.1111/cas.14148 · Cited by 104
Kim, J. Y., Lee, K. H., Kang, J., Borcoman, É., Saâda-Bouzid, E., Kronbichler, A., Hong, S. H., Rezende, L. F. M., Ogino, S., Keum, N., et al. (2019) · Cancers · doi:10.3390/cancers11111699 · Cited by 104
Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer
Dhar, M., Wong, J., Che, J., Matsumoto, M. M., Grogan, T., Elashoff, D. A., Garon, E. B., Goldman, J. W., Christen, E. S., Carlo, D. D., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19245-w · Cited by 106
An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma
Grünwald, V., Eberhardt-Wetherington, B., Bex, A., Flörcken, A., Gauler, T. C., Derlin, T., Panzica, M., Dürr, H. R., Grötz, K. A., Giles, R. H., et al. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0034-9 · Cited by 103
Self-citationZhang, B., Wu, Q., Zhou, Y. L., Guo, X., Ge, J., & Fu, J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.08.014 · Cited by 103
Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives
Weenink, B., French, P. J., Smitt, P. A. E. S., Debets, R., & Geurts, M. (2020) · Cancers · doi:10.3390/cancers12030751 · Cited by 106
McKay, R. R., McGregor, B. A., Xie, W., Braun, D. A., Wei, X. X., Kyriakopoulos, C. E., Zakharia, Y., Maughan, B. L., Rose, T. L., Stadler, W. M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02295 · Cited by 103
Self-citationCheckpoint inhibitors in chronic kidney failure and an organ transplant recipient
Herz, S., Höfer, T., Papapanagiotou, M., Leyh, J., Meyenburg, S., Schadendorf, D., Ugurel, S., Roesch, A., Livingstone, E., Schilling, B., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.07.026 · Cited by 102
New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy
Zarrabi, K. K., Fang, C.-H., & Wu, S. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0374-y · Cited by 102
Immunotherapy-related hepatitis: real-world experience from a tertiary centre
Cheung, V., Gupta, T., Payne, M., Middleton, M. R., Collier, J. D., Simmons, A., Klenerman, P., Brain, O., & Cobbold, J. (2019) · Frontline Gastroenterology · doi:10.1136/flgastro-2018-101146 · Cited by 102
Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm
Robert, C., Marabelle, A., Herrscher, H., Caramella, C., Rouby, P., Fizazi, K. S., & Besse, B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0399-6 · Cited by 105
Sha, C. M., Lehrer, E. J., Hwang, C., Trifiletti, D. M., Mackley, H. B., Drabick, J. J., & Zaorsky, N. G. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.07.035 · Cited by 102
Kim, H., Shim, B. Y., Lee, S., Lee, J. Y., Lee, H. J., & Kim, I.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189795 · Cited by 109
Bilen, M. A., Subudhi, S. K., Gao, J., Tannir, N. M., Tu, S., & Sharma, P. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0139-8 · Cited by 101
Self-citationResistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action
Durán, I., Lambea, J., Maroto, P., González-Larriba, J. L., Flores, L. E., Granados-Principal, S. M., Graupera, M., Sáez, B., Vivancos, A. P., & Casanovas, O. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0463-4 · Cited by 101
Hyperprogression as a distinct outcome after immunotherapy
Fuentes‐Antrás, J., Provencio, M., & Díaz‐Rubio, E. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.07.006 · Cited by 103
Glutathione Metabolism in Renal Cell Carcinoma Progression and Implications for Therapies
Xiao, Y., & Meierhofer, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153672 · Cited by 104
Xie, C., Duffy, A. G., Brar, G. S., Fioravanti, S., Mabry‐Hrones, D., Walker, M., Bonilla, C. M., Wood, B. J., Citrin, D. E., Ramirez, E. M. G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3624 · Cited by 102
Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy
Zhang, B., & Cheng, P. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01275-6 · Cited by 102
Guo, X., Nie, H., Zhang, W., Li, J., Ge, J., Xie, B., Hu, W., Zhu, Y., Zhong, N., Zhang, X., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.01.001 · Cited by 100
Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma
Lalani, A.-K. A., Xie, W., Braun, D. A., Kaymakcalan, M., Bossé, D., Steinharter, J. A., Martini, D. J., Simantov, R., Lin, X., Wei, X. X., et al. (2020) · European Urology Oncology · doi:10.1016/j.euo.2019.09.001 · Cited by 100
Self-citationSridharan, V., Gjini, E., Liao, X., Chau, N. G., Haddad, R. I., Severgnini, M., Hammerman, P. S., El‐Naggar, A. K., Freeman, G. J., Hodi, F. S., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0031 · Cited by 100
Metadata
- Authors
- Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., Castellano, D., Choueiri, T. K., Gurney, H., Donskov, F., Bono, P., Wagstaff, J., Gauler, T. C., Ueda, T., Tomita, Y., Schutz, F. A., Kollmannsberger, C., Larkin, J., Ravaud, A., Simon, J. S., Xu, L.-A., Waxman, I. M., & Sharma, P.
- Affiliations
- Brigham and Women's Hospital (US)
- Institut Gustave Roussy (FR)
- Beth Israel Deaconess Medical Center (US)
- Roswell Park Comprehensive Cancer Center (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- Stanford Cancer Institute (US)
- University of Washington (US)
- Vanderbilt University Medical Center (US)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Fox Chase Cancer Center (US)
- Hospital Universitario 12 De Octubre (ES)
- Westmead Hospital (AU)
- Aarhus University Hospital (DK)
- University of Helsinki (FI)
- Swansea University (GB)
- Essen University Hospital (DE)
- Chiba Cancer Center (JP)
- Niigata University (JP)
- Beneficência Portuguesa de São Paulo (BR)
- BC Cancer Agency (CA)
- Royal Marsden Hospital (GB)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Bristol-Myers Squibb (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Motzer, Robert J.
- Escudier, Bernard
- McDermott, David F.
- George, Saby
- Hammers, Hans J.
- Tykodi, Scott S.
- Sosman, Jeffrey A.
- Procopio, Giuseppe
- Plimack, Elizabeth R.
- Castellano, Daniel
- Choueiri, Toni K.
- Gurney, Howard
- Donskov, Frede
- Bono, Petri
- Wagstaff, John
- Gauler, Thomas C.
- Ueda, Takeshi
- Tomita, Yoshihiko
- Schutz, Fabio A.
- Kollmannsberger, Christian
- Larkin, James
- Ravaud, Alain
- Sharma, Padmanee
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-05
- Volume
- 373
- Issue
- 19
- Pages
- 1803-1813
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5719487
- OpenAlex
- W2222086386
- Cited by
- 5,807
- References
- 36
- Citations by year
- 2026: 173 · 2025: 255 · 2024: 367 · 2023: 449 · 2022: 535 · 2021: 669 · 2020: 723 · 2019: 669 · 2018: 719 · 2017: 691 · 2016: 511 · 2015: 36
- FWCI
- 515.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Lirias (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- nivolumab, everolimus, PD-1 inhibitors, mTOR inhibitors, overall survival, objective response rate, progression-free survival, treatment-related adverse events, anti-angiogenic therapy, immune checkpoint inhibitors, mTOR inhibition, fatigue, anemia, previously treated patients
- MeSH terms
- Everolimus, Nivolumab, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Quality of Life, Survival Analysis, Sirolimus, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
